COMMUNIQUÉS West-GlobeNewswire

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
21/10/2026
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today [...]
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
21/10/2026
Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidate) CII in adults [...]
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
21/10/2026
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
21/10/2026
DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third [...]
Arbor Biotechnologies Nominates Three Gene Editing Development Candidates for ALS, with Potential to Address Up to 97% of People Living with the Disease
21/10/2026
Programs span familial and sporadic ALS, advancing Arbor’s strategic focus on the disease First CNS investigational new drug (IND) filings are anticipated in 2027 Milestone builds on clinical development expertise [...]
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
21/10/2026
— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- [...]
Integra LifeSciences Reports Third Quarter 2026 Financial Results
21/10/2026
PRINCETON, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending [...]
Vistin Pharma ASA: Invitation to Q3 2026 conference call
21/10/2026
Oslo, Norway, 21 October 2026 Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2026 results on Thursday 29th of October 2026. Vistin Pharma will host a conference call for all shareholders and interested [...]
Promising Early Safety Data as Quell Therapeutics Advances QEL-005 – a Novel Engineered nTreg Therapy – to Second Dose Cohort in CHILL Phase 1/2 Trial in Difficult-to-Treat Rheumatoid Arthritis and Systemic Sclerosis
21/10/2026
Safe completion of the first dose cohort in which QEL-005 was well tolerated, with no dose-limiting toxicities (DLTs), no treatment-related adverse events of special interest (AESIs) and no serious adverse events (SAEs [...]
NRG Therapeutics Announces a PET Biodistribution Trial of Lead Clinical Asset NRG5051
21/10/2026
STEVENAGE, United Kingdom, Oct. 21, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in [...]
KFSH Forecasts Emergency Demand 24 Hours Ahead with AI as Time to See a Physician Falls 42%
21/10/2026
RIYADH, Saudi Arabia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is using artificial intelligence to forecast Emergency Department demand 24 hours ahead, double its [...]
Bioxodes BIOX-101 Phase 2a data show statistically significant reduction in perihematomal edema growth in intracerebral hemorrhage
21/10/2026
First disclosure of new imaging analyses and one-year functional outcome were presented at the World Stroke Congress today Change in normalized hemorrhage volume was significantly lower with BIOX-101 versus standard of [...]
Avance Clinical to Meet European Biotechs at ESMO Congress 2026 and Appoints Wendy Hamon as Senior Vice President, Oncology Center of Excellence
21/10/2026
Executive Medical Director Dr George Peoples to discuss oncology programs from preclinical through Phase II in Madrid ADELAIDE, Australia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global full-service CRO [...]
Kylo Peptides Marks Record Month as Brand Searches Nearly Triple
21/10/2026
Sheridan, Wyoming, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ], a research peptide supplier, recorded its highest month of brand search interest in September 2026. Estimated US searches [...]
ONWARD Medical Announces the Appointment of Fouad Azzam to its Board of Directors
21/10/2026
Fouad Azzam is a Partner with EQT Life Sciences, bringing extensive experience investing in and supporting fast-growing medical technology and life sciences companies EINDHOVEN, the Netherlands, Oct. 21, 2026 (GLOBE [...]
First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial
21/10/2026
First Patient Treated in the C-FLASH-01 ConformalFLASH ® Clinical Trial Louvain-la-Neuve, Belgium, October 21, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and [...]
Premier patient traité dans le cadre de l’essai clinique C-FLASH-01 sur ConformalFLASH®
21/10/2026
Premier patient traité dans le cadre de l’essai clinique C-FLASH-01 sur ConformalFLASH ® Louvain-la-Neuve, Belgique, le 21 octobre 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’ [...]
F2G and Shionogi Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome® Followed by Standard of Care in Invasive Aspergillosis in Late-Breaking Oral Presentation at IDWeek 2026
21/10/2026
Oral olorofim was non-inferior to AmBisome ® followed by standard of care (AmBisome ® +SOC), with Day 42 all-cause mortality of 23.8% for olorofim versus 24.3% for AmBisome ® +SOC in patients with invasive aspergillosis [...]
Teknova Announces Pricing of $40 Million Public Offering of Common Stock
21/10/2026
HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]

Pages